Please select an option below to help us tailor your newsletter to best suit your content interests!
The APP Oncology Summit is coming to Nashville, TN on Friday, September 5 and Saturday, September 6, 2025 — and our West network will be well represented! Christy Izzett, our Director of Advanced Practice Providers, is serving on the Planning Committee, and Dr. Axel Grothey, Medical Oncologist, will be on Faculty presenting on Molecular Profiling… Read more »
Exciting updates in GI Cancers! Dr. Axel Grothey from West Cancer Center shared groundbreaking insights at the Total Health Spring Oncology Review and Renew Conference. He highlighted major advancements in targeted therapies and precision medicine for GI cancers. Here are the key highlights: Gastro-Esophageal Junction (GEJ) Cancers: Dr. Grothey revealed a new biomarker, Claudin 18.2… Read more »
Our West family is proud to have several of our oncologists publish research being presented at the upcoming American Society of Clinical Oncology Meeting, taking place June 4 – 8. West Cancer Center doctors Schwartzberg, Grothey, A. VanderWalde, Vaena, Vidal and ElNaggar are some of the renowned physicians being recognized at this esteemed event for… Read more »
Axel Grothey, MD, medical oncologist and our Director of Gastrointestinal Cancer Research, discusses the role of precision medicine in colorectal cancer (CRC) with OncLive. Grothey says, “With the rise of molecular profiling, the field of CRC has shifted away from a one-size-fits-all approach and entered an era of precision medicine. Notably, molecular profiling guides the… Read more »
Axel Grothey, MD The New England Journal of Medicine (NEJM) has recently published an editorial entitled “Pembrolizumab as first-line therapy in mismatch repair-deficient advanced colorectal cancer: A new standard of care” written by West Cancer Center’s GI Medical Oncology Lead and GI Oncology Clinical Research Director, Dr. Axel Grothey. Click the link below… Read more »